Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 10, 2026 04:30 ET | Source: Kainova Therapeutics

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

Kainova Therapeutics announces positive Phase I results for DT‑9081, showing strong safety, target engagement and early anti‑tumor activity.
February 10, 2026 03:00 ET | Source: Kainova Therapeutics

Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies

Kainova Therapeutics announces a $32M CAD first close of its Series B financing, led by Investissement Québec with participation from existing investors.